The most auspicious element of the trial IMO is that we are not dealing with an entity (the science behind Brilacidin) that can have a bad day, such as can happen with a human athlete.

Brilacidin's science, both in regards to safety and efficacy, is going to work the same day in and day out. It will seek out viruses and kill them, period.

Safety profile has stayed steady throughuout prior trials so no need to believe it won't continue with this trial. Selectivity Index of 426 makes a pretty good statement as to that end.

Don't know if everybody else is as confident as me. I know nobody will ever say we are a lock for great trial results, but I can't see how we should have more than a 1 or 2% chance of failing (at the most), and I only say that as crazy things happen in life.